OncoMatch/Clinical Trials/NCT04972942
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
Is NCT04972942 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Daratumumab for t-cell acute lymphoblastic leukemia.
Treatment: Daratumumab — A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Prior therapy
Must have received: chemotherapy — re-induction therapy for relapsed T-cell LLy
relapsed T-cell LLy with complete response after re-induction therapy
Cannot have received: autologous stem cell transplant
May not have had a prior autologous or allogenic stem cell transplant
Cannot have received: allogeneic stem cell transplant
May not have had a prior autologous or allogenic stem cell transplant
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Loma Linda University Children's Hospital · Loma Linda, California
- University of California · Los Angeles, California
- University of California · San Francisco, California
- Children's Hospital Colordao · Aurora, Colorado
- Children's National Medical Center · Washington D.C., District of Columbia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify